A型肉毒毒素治疗中老年带状疱疹后神经痛共病焦虑抑郁的临床疗效

张尧尧; 陈立平; 陈艳茹; 孙晴; 王雪薇; 申文

doi:10.3969/j.issn.2096-3882.2022.06.003

A型肉毒毒素治疗中老年带状疱疹后神经痛共病焦虑抑郁的临床疗效

1. 徐州医科大学附属医院麻醉科, 江苏徐州 221002;
2. 徐州医科大学附属医院疼痛科

详细信息

通讯作者:
申文,E-mail:shenwen1598@sina.com

中图分类号: R752.1
计量
- 文章访问数: 1061
- HTML全文浏览量: 1
- PDF下载量: 591
出版历程
- 收稿日期: 2022-05-19
- 修回日期: 2022-06-05

Clinical effect of botulinum toxin A on anxiety and depression in middle-aged and elderly patients with postherpetic neuralgia

1. Department of Anesthesiology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu 221002, China;
2. Department of Pain, the Affiliated Hospital of Xuzhou Medical University

摘要

摘要: 目的探讨A型肉毒毒素对中老年带状疱疹后神经痛(PHV)患者的疗效,及对其共病焦虑抑郁状态的影响。方法选取2019年12月—2021年1月于徐州医科大学附属医院就诊的PHN患者,共100例。按照随机数字表法,将患者分为2组:A型肉毒素组(BTX-A组)和对照组(C组),每组50例。于治疗前(T0)、治疗后 1 周(T1)、4周(T2)、12周(T3)评估疼痛数字评分(NRS)、患者健康问卷抑郁量表(PHQ-9)评分、广泛性焦虑障碍量表(GAD-7)评分;治疗12周后评估2组患者总体睡眠质量评分(SQS)的改善情况。记录治疗后患者平均每日口服加巴喷丁的剂量、阿片类药物的使用情况和不良反应的发生率。结果与T0相比,2组患者治疗后T1~T3时间点 NRS、GAD-7、PHQ-9评分均降低(P<0.05);与C组相比,BTX-A组治疗后各时间点 NRS、GAD-7和PHQ-9评分均明显改善,差异有统计学意义(P<0.05)。治疗12周后,BTX-A组患者SQS评分较C组明显改善(P＜0.05)。2组患者口服加巴喷丁剂量比较,差异无统计学意义(P＞0.05),阿片类药物的使用率无统计学差异(P＞0.05)。2组不良反应的发生率比较,差异无统计学意义(P＞0.05)。结论 A型肉毒毒素能够缓解中老年PHN患者的疼痛,并在一定程度上改善焦虑抑郁症状。
- A型肉毒毒素 /
- 带状疱疹后神经痛 /
- 焦虑 /
- 抑郁
Abstract: Objective To investigate the therapeutic effect of botulinum toxin A on middle-aged and elderly patients with postherpetic neuralgia (PHN) as well as anxiety and depression. Methods A total of 100 PHN patients who were admitted to the Affiliated Hospital of Xuzhou Medical University from December 2019 to January 2021 were enrolled. According to the random number table method, they were divided into two groups (n=50): a botulinum toxin A group (group BTX-A) and a control group (group C). Both groups were compared for their numeric rating scale (NRS) scores, patient health questionnaire depression scale (PHQ-9) scores, and generalized anxiety disorder scale (GAD-7) scores before treatment (T0), one week after treatment (T1), four weeks after treatment (T2), and 12 weeks after treatment (T3). After 12 weeks of treatment, the improvement of the overall sleep quality scores (SQS) in both groups was assessed. The doses of daily oral gabapentin and opioids, and the incidence of adverse reactions were recorded. Results Compared with those at T0, both groups presented decreases in the scores of NRS, GAD-7 and PHQ-9 at T1 to T3 after treatment. The scores of NRS, GAD-7 and PHQ-9 in group BTX-A were significantly improved compared with those in group C at each time points after treatment (P<0.05). After 12 weeks of treatment, group BTX-A showed significantly improved SQS scores compared with group C (P<0.05). There was no difference in the doses of oral gabapentin and the use of opioids (P>0.05). No statistical difference was found in the incidence of adverse reactions between the two groups (P>0.05). Conclusions Botulinum toxin A can relieve pain in middle-aged and elderly patients with PHN, and improve anxiety and depression to a certain extent.
- botulinum toxin A /
- postherpetic neuralgia /
- anxiety /
- depression

HTML全文

参考文献(17)

[1]	Koga R, Yamada K, Ishikawa R, et al.Association between treatment-related early changes in psychological factors and development of postherpetic neuralgia[J].J Anesth, 2019, 33(6):636-641.
[2]	Mallick-Searle T, Snodgrass B, Brant JM.Postherpetic neuralgia:epidemiology, pathophysiology, and pain management pharmacology[J].J Multidiscip Healthc, 2016, 9:447-454.
[3]	Zhu Q, Zheng H, Qu H, et al.Epidemiology of herpes zoster among adults aged 50 and above in Guangdong, China[J].Hum Vaccin Immunother, 2015, 11(8):2113-2118.
[4]	Thenganatt MA, Fahn S.Botulinum toxin for the treatment of movement disorders[J].Curr Neurol Neurosci Rep, 2012, 12(4):399-409.
[5]	Yuan RY, Sheu JJ, Yu JM, et al.Botulinum toxin for diabetic neuropathic pain:a randomized double-blind crossover trial[J].Neurology, 2009, 72(17):1473-1478.
[6]	彭彬, 申起, 董红娟, 等.A型肉毒毒素对偏侧面肌痉挛和良性特发性眼睑痉挛患者焦虑/抑郁状态的影响[J].中国神经精神疾病杂志, 2017, 43(10):603-607.
[7]	Zhang Q, Wu W, Fan Y, et al.The safety and efficacy of botulinum toxin A on the treatment of depression[J/OL].Brain Behav, 2021, 11(9):e2333.
[8]	Zhang H, Zhang H, Wei Y, et al.Treatment of chronic daily headache with comorbid anxiety and depression using botulinum toxin A:a prospective pilot study[J].Int J Neurosci, 2017, 127(4):285-290.
[9]	吴征元, 杜佳溪, 孙悦, 等.糖尿病对带状疱疹病人的预后影响及其危险因素研究 [J].中国疼痛医学杂志, 2021, 27(4):262-268.
[10]	Du J, Sun G, Ma H, et al.Prevalence and risk factors of anxiety and depression in patients with postherpetic neuralgia:a retrospective study[J].Dermatology, 2021, 237(6):891-895.
[11]	Schlereth T, Heiland A, Breimhorst M, et al.Association between pain, central sensitization and anxiety in postherpetic neuralgia[J].Eur J Pain, 2015, 19(2):193-201.
[12]	Wollmer MA, Makunts T, Krüger THC, et al.Postmarketing safety surveillance data reveals protective effects of botulinum toxin injections against incident anxiety[J/OL].Sci Rep, 2021, 11(1):24173.
[13]	曹宇萌, 李蒙, 王凤志, 等. A型肉毒毒素治疗慢性偏头痛共病抑郁焦虑的研究进展[J].中国神经精神疾病杂志, 2019, 45(10):618-622.
[14]	Blumenfeld AM, Tepper SJ, Robbins LD, et al.Effects of onabotulinumtoxinA treatment for chronic migraine on common comorbidities including depression and anxiety[J].J Neurol Neurosurg Psychiatry, 2019, 90(3):353-360.
[15]	Zhu X, Hu P, Fan Z, et al.Effects of mindfulness-based stress reduction on depression, anxiety, and pain in patients with postherpetic neuralgia[J].J Nerv Ment Dis, 2019, 207(6):482-486.
[16]	Alam M, Barrett KC, Hodapp RM, et al.Botulinum toxin and the facial feedback hypothesis:can looking better make you feel happier[J] J Am Acad Dermatol, 2008, 58(6):1061-1072.
[17]	Finzi E, Wasserman E.Treatment of depression with botulinum toxin A:a case series[J].Dermatol Surg, 2006, 32(5):645-649;discussion 649-650.